3 ways to prevent head and neck cancer
Katharine Price, M.D., a medical oncologist with the Mayo Clinic Comprehensive Cancer Center in Rochester, says there are three ways to reduce your risks and help prevent head and neck cancer.
Tobacco and alcohol use increase the risk of non-HPV tumors, while HPV is responsible for about 70% of head and neck cancers.
"What's important about that is they have different biology and are much more treatable, meaning they respond better to treatments and tend to have a higher cure rate. We're sort of treating those differently than how we treat some of the non-HPV cancers," Dr. Price says.
Surgery, radiation and chemotherapy are all treatment options, but Dr. Price says it is better to reduce the risks of infection.
"The big three: no smoking tobacco use, minimizing alcohol and then HPV vaccination," she says.
"We know that smoking and alcohol are big risk factors for head and neck cancer if you do both. This increases your risk even more," Dr. Price says.
And she encourages eating a healthy diet.
"We really should be striving to have a good whole-food diet, trying to minimize eating processed foods and refined sugars," Dr. Price says.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
4 days ago
- Web Release
AI-ECG tools can help clinicians identify heart issues early in women planning to have children
Every year, some mothers die after giving birth due to heart problems, and many of these deaths could be prevented. The ability to screen for heart weakness before pregnancy could play a crucial role in identifying women who may need additional care to improve pregnancy outcomes. Mayo Clinic researchers, led by Anja Kinaszczuk, D.O., and Demilade Adedinsewo, M.B., Ch.B., tested artificial intelligence (AI) tools, using recordings from an electrocardiogram (ECG) and a digital stethoscope, to find unknown heart problems in women of childbearing age seen in primary care. Study findings published in the Annals of Family Medicine show high diagnostic performance of these technologies to detect left ventricular ejection fraction below 50%, indicating heart muscle weakness. These tools were tested on two groups of women aged 18 to 49: Group 1: 100 women already scheduled for an echocardiogram (the best test to evaluate heart muscle function). They also had a standard clinical ECG and digital stethoscope recording of the heart's electrical activity and heart sounds. Group 2: 100 women seen for routine primary care visits to see how often the AI tools would find heart problems. The AI-ECG demonstrated an area under the curve (AUC) of 0.94, while the AI digital stethoscope, Eko DUO, achieved an even higher AUC of 0.98, indicating strong diagnostic accuracy. In the second cohort, the prevalence of positive AI screening results was 1% for the AI-ECG and 3.2% for the AI-stethoscope. 'Statistically, nearly half of pregnancies in this country are unplanned, and approximately 1% to 2% of women may have heart problems they don't know about. Our research findings suggest that these AI tools could be used to screen women before pregnancy, allowing for improved pregnancy planning and risk stratification, early treatment, and better health outcomes which addresses a critical gap in current maternal care,' says Dr. Adedinsewo, a cardiologist and senior author of the study. This research builds upon earlier published studies, including a pilot prospective study evaluating AI digital tools to detect pregnancy-related cardiomyopathy among obstetric patients in the U.S. and a pragmatic randomized clinical trial of women in Nigeria who were pregnant or had recently given birth. Collectively, this research highlights the potential of AI to modernize cardiovascular screening, enabling earlier identification and management of heart muscle weakness in women of reproductive age. Further research is underway to explore the potential of using these technologies to screen for heart weakness in broader populations. Mayo Clinic has licensed the underlying technology to Eko Health for its digital stethoscope with embedded ECG electrodes and to Anumana for the 12-lead ECG. Mayo Clinic and some study authors have a financial interest in this technology. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
Zawya
4 days ago
- Zawya
AI-ECG tools can help clinicians identify heart issues early in women planning to have children
Dubai, United Arab Emirates — Every year, some mothers die after giving birth due to heart problems, and many of these deaths could be prevented. The ability to screen for heart weakness before pregnancy could play a crucial role in identifying women who may need additional care to improve pregnancy outcomes. Mayo Clinic researchers, led by Anja Kinaszczuk, D.O., and Demilade Adedinsewo, M.B., Ch.B., tested artificial intelligence (AI) tools, using recordings from an electrocardiogram (ECG) and a digital stethoscope, to find unknown heart problems in women of childbearing age seen in primary care. Study findings published in the Annals of Family Medicine show high diagnostic performance of these technologies to detect left ventricular ejection fraction below 50%, indicating heart muscle weakness. These tools were tested on two groups of women aged 18 to 49: Group 1: 100 women already scheduled for an echocardiogram (the best test to evaluate heart muscle function). They also had a standard clinical ECG and digital stethoscope recording of the heart's electrical activity and heart sounds. Group 2: 100 women seen for routine primary care visits to see how often the AI tools would find heart problems. The AI-ECG demonstrated an area under the curve (AUC) of 0.94, while the AI digital stethoscope, Eko DUO, achieved an even higher AUC of 0.98, indicating strong diagnostic accuracy. In the second cohort, the prevalence of positive AI screening results was 1% for the AI-ECG and 3.2% for the AI-stethoscope. "Statistically, nearly half of pregnancies in this country are unplanned, and approximately 1% to 2% of women may have heart problems they don't know about. Our research findings suggest that these AI tools could be used to screen women before pregnancy, allowing for improved pregnancy planning and risk stratification, early treatment, and better health outcomes which addresses a critical gap in current maternal care," says Dr. Adedinsewo, a cardiologist and senior author of the study. This research builds upon earlier published studies, including a pilot prospective study evaluating AI digital tools to detect pregnancy-related cardiomyopathy among obstetric patients in the U.S. and a pragmatic randomized clinical trial of women in Nigeria who were pregnant or had recently given birth. Collectively, this research highlights the potential of AI to modernize cardiovascular screening, enabling earlier identification and management of heart muscle weakness in women of reproductive age. Further research is underway to explore the potential of using these technologies to screen for heart weakness in broader populations. Mayo Clinic has licensed the underlying technology to Eko Health for its digital stethoscope with embedded ECG electrodes and to Anumana for the 12-lead ECG. Mayo Clinic and some study authors have a financial interest in this technology. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
Web Release
08-07-2025
- Web Release
Mayo Clinic researchers link inherited mutation to fatty liver disease
Researchers at Mayo Clinic's Center for Individualized Medicine have discovered a rare genetic variant that can directly cause metabolic dysfunction-associated steatotic liver disease, formerly known as nonalcoholic fatty liver disease. Until now, scientists believed the disease resulted from a combination of genetic and environmental factors. This study, published in Hepatology, reveals that in some cases, a single inherited variant can be the primary driver. The researchers identified this variant in the MET gene, which regulates liver repair and fat metabolism. When the gene malfunctions, fat accumulates in liver cells and triggers inflammation. Over time, this leads to fibrosis and scarring, which stiffens the liver. In severe cases, the disease progresses to cirrhosis, resulting in irreversible liver damage or liver cancer. Metabolic dysfunction-associated steatotic liver disease affects about one-third of adults worldwide. Its advanced form, metabolic dysfunction-associated steatohepatitis, is expected to become the leading cause of cirrhosis and the reason for liver transplants in the coming years. 'This discovery opens a window into how rare inherited genetic variants can drive common diseases,' says lead author Filippo Pinto e Vairo, M.D, Ph.D., medical director of the Program for Rare and Undiagnosed Diseases at Mayo Clinic's Center for Individualized Medicine. 'It provides new insights into this disease pathogenesis and potential therapeutic targets for future research.' The discovery emerged from the genomic data of a woman and her father with metabolic dysfunction-associated steatohepatitis. They had no history of diabetes or high cholesterol, two common risk factors for fat buildup in the liver. With no clear explanation, researchers examined the DNA from more than 20,000 genes to find answers. They found a small but potentially significant error in the MET gene. In collaboration with the Medical College of Wisconsin's John & Linda Mellowes Center for Genomic Sciences and Precision Medicine, led by Raul Urrutia, M.D., the scientists determined that the mutation disrupted a critical biological process. Genes are made up of chemical letters that provide instructions for the body's functions. In this case, a single swapped letter — among thousands — scrambled the message, preventing the liver from properly processing fat. This rare variant, found in the family, has not been reported in existing literature or public databases. 'This study demonstrates that rare diseases are not rare but often hidden in the large pool of complex disorders, underscoring the immense power of individualized medicine in identifying them, and enabling the design of advanced diagnostics and targeted therapies,' Dr. Urrutia says. To explore the variant's broader impact, researchers turned to Mayo Clinic's Tapestry study, a large-scale exome sequencing effort aimed at uncovering genomic drivers of disease. The Tapestry study analyzed germline DNA from over 100,000 participants across the U.S., creating a comprehensive genomic data repository that supports research into both well-known and emerging health conditions. Among nearly 4,000 adult Tapestry participants with metabolic dysfunction-associated steatotic liver disease, about 1% carried rare, potentially causative variants in the same MET gene. Of these, nearly 18% had variants in the same critical region as the initial woman and her father, further supporting its role in liver disease. 'This finding could potentially affect hundreds of thousands, if not millions, of people worldwide with or at risk for metabolic dysfunction-associated steatotic liver disease,' says Konstantinos Lazaridis, M.D., a lead author and the Carlson and Nelson Endowed Executive Director for the Center for Individualized Medicine. Dr. Lazaridis emphasized the significance of this discovery as it relates to the Tapestry study's impactful contributions. 'Once a pathogenic variant is discovered, interrogating our Tapestry data repository is giving us a clearer lens into the hidden layers of disease, and this discovery is one of the first to demonstrate its scientific significance,' Dr. Lazaridis says. 'This finding highlights the profound value of studying familial diseases and the merit of large-scale genomic datasets, which can reveal rare genetic variations with broader implications for population health.' This discovery also reflects the importance of integrating genomics into clinical care at Mayo Clinic, where teams use advanced technologies to help solve complex medical mysteries. Since its launch in 2019, the Program for Rare and Undiagnosed Diseases has helped more than 3,200 patients with complex and serious conditions gain access to comprehensive genomic testing. It collaborates with nearly 300 clinicians from 14 divisions across the enterprise to bring precision diagnostics to patients with rare conditions, including rare liver diseases. Future studies will explore how this genomic discovery in metabolic dysfunction-associated steatotic liver disease can inform targeted treatments and improve disease management. For a complete list of authors, disclosures and funding, review the study.
